Uroplasty CEO Steps Down

The CEO of Minnetonka-based Uroplasty has resigned, the medical devices company announced Friday.

David B. Kaysen tendered his resignation as president, CEO and board of directors member, effective Friday.

“Dave assumed the CEO role when Uroplasty had virtually all of its operations in Europe and generated only $6.4 million in revenue. He departs with the company generating over $22 million in annual sales, largely fueled by growth in Urgent PC sales. We truly appreciate all of Dave’s contributions and wish him the best in his future endeavors,” the news release quoted Uroplasty Chairman James Stauner.

Kaysen has been president and CEO since May 2006, according to the company. Twin Cities Business reports that he resigned of his own accord, although Uroplasty did not disclose the reasons for his departure to the publication.

Click here to read the full Twin Cities Business article.

Uroplasty named independent director Robert C. Kill as interim CEO while the company searches for a permanent head. Kill has been a director with the company since 2010 and is an operating partner with Altamont Capital Partners, a private equity firm.